Concepedia

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger, Inge Christoffer Olsen, Rolf Anton Klaasen, David J. Warren, Cato Mørk,

Journal of Internal Medicine · 2022 · 35 citations · 31 references

DOIFull text

Open access

Abstract

Several risk factors for ADAb formation during early-phase infliximab treatment were identified. This knowledge provides a basis for treatment strategies to mitigate the formation of ADAb and identify patients in whom these measures are of particular importance.

References

31

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Yoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 105.5K citations

, , +21

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.1K citations

, , +5

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.8K citations · Full text

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · New England Journal of Medicine · 2010 · 3.1K citations · Full text

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld et al. · The Lancet · 1999 · 2.3K citations

, , +14